

**Amendments to the Claims:**

Claims 1-15 (Cancelled).

Claim 16 (New): A method for treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering 2 to 4 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and an effective, non-toxic and pharmaceutically acceptable amount of insulin, to a mammal in need thereof.

Claim 17 (New): A method according to claim 16, which comprises administering 2 mg per day of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 18 (New): A method according to claim 16, which comprises administering 4 mg per day of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 19 (New): A method according to claim 16, which comprises administering a unit dosage form comprising 1, 2, 3 or 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

Claim 20 (New): A method according to claim 19, comprising administering a unit dosage form comprising 1 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 21 (New): A method according to claim 19, comprising administering a unit dosage form comprising 2 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 22 (New): A method according to claim 19, comprising administering a unit dosage form comprising 4 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form.

Claim 23 (New): A method according to claim 19, wherein said unit dosage form is a tablet or a capsule.

Claim 24 (New): A method according to claim 16, which comprises administering a formulation which comprises both of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

Claim 25 (New): A method according to claim 16, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

Claim 26 (New): A method according to claim 16, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

Claim 27 (New): A method according to claim 16, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

Claim 28 (New): A method according to claim 27, wherein said pharmaceutically acceptable salt is a maleate salt.

Claim 29 (New): A method according to claim 16, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

Claim 30 (New): A method according to claim 16, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

Claim 31 (New): A method according to claim 29, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 32 (New): A method according to claim 30, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 33 (New): A method according to claim 16, which comprises administering a tablet or a capsule comprising a pharmaceutically acceptable salt of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, and insulin.

Claim 34 (New): A method according to claim 16, which comprises administering a tablet or a capsule comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, or a tautomer thereof, in a pharmaceutically acceptable form, and insulin.

Claim 35 (New): A method for treatment of Type II diabetes mellitus in a mammal, which method comprises administering 2 to 4 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and an effective, non-toxic and pharmaceutically acceptable amount of insulin, to a mammal in need thereof.